The New Jersey State Board of Pharmacy temporarily suspended the license of pharmacist Nittal K. Lodha and the permit of Woodbury Family Pharmacy for allegedly practicing unsafely, maintaining unsanitary conditions, and interfering with patients' rights to transfer prescriptions to other pharmacies. The suspension was ratified on June 24, 2026.
Temporary suspension of pharmacist license and pharmacy permit, with possibility of limited reinstatement under conditions set in the order.
In-house legal teams should review pharmacy services agreements and vendor contracts with pharmacies to ensure they include clauses requiring compliance with all applicable health and safety regulations, patient choice rights, and quality standards. They should also verify that contracts allow for termination or suspension in case of regulatory actions, and that they address patient data handling and consent in accordance with health privacy laws.
Entity
Woodbury Family Pharmacy
Industry
HealthcareOfficial Press Release
https://www.njoag.gov/state-board-of-pharmacy-temporarily-suspends-license-and-shuts-down-pharmacy-of-gloucester-county-pharmacist/
2026 0707 20260623 28RI03035700 Order
http://www.njoag.gov/wp-content/uploads/2026/07/2026-0707_20260623_28RI03035700_Order.pdf
New Jersey Attorney General Enforcement Page
https://www.njoag.gov/about/divisions-and-offices/division-of-consumer-affairs/
"pharmacist Nittal K. Lodha, owner and operator of Woodbury Family Pharmacy"
"repeatedly disregarded patients’ requests to stop filling their prescriptions and transfer them to other pharmacies"
"temporarily suspends the license and shuts down the pharmacy"
$220.0M
A 36-attorney-general coalition resolved allegations that General Motors collected and sold identifiable driver behavior and location data to data brokers, which supplied it to insurers for use in assessing drivers and potentially raising premiums. The $220 million nationwide settlement requires affirmative express consent before collecting or disclosing driving and location data, limits data collection, and imposes privacy-program assessments and dealership oversight and training.
New Jersey, the FTC, and a coalition of 19 other states sued Dollar General, alleging that customers were repeatedly charged more at checkout than prices displayed on shelves, tags, and advertisements. The complaint alleges deceptive pricing practices and inadequate safeguards despite consumer complaints; the release does not describe a settlement, penalty, or other remedy imposed.
New Jersey joined a coalition of state attorneys general in filing a notice in Character Technologies, Inc.’s bankruptcy proceedings, raising concerns about the company’s safety and privacy practices and the sensitive conversations it holds, including those involving children and mental health. The states seek safeguards for consumers’ personal information in any sale or transfer of the company’s business or assets; the release does not report a fine or final finding of violations.
A multistate coalition co-led by New Jersey won a federal court order rejecting the Trump Administration’s decision not to request funding for the CFPB. The order struck down that decision and directed the Administration to follow the law and fund the agency; no monetary penalty or privacy violation is described.
New Jersey’s Attorney General and Division of Consumer Affairs alerted the public that three synthetic kratom-related compounds became illegal to possess or sell in the state under a temporary federal scheduling order. The release describes a controlled-substance alert, not a privacy enforcement action, and identifies no company, privacy violation, or monetary penalty.
$2.3M
Laboratory Corporation of America Holdings agreed to pay $2,287,455 to participating states and strengthen its security and vendor-management practices following an investigation into the 2019 breach at its debt-collection vendor, AMCA. The breach potentially exposed information of more than 27.5 million people nationwide, including sensitive information belonging to approximately 10.2 million LabCorp patients.